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1. Construction of Vectors.
Oligonucleotides synthesized and used as PCR or RT-PCR primers were purchased from Sigma-
Genosys. Restriction and other pertinent sequences are marked in bold.
Primer Sequence (5’ 3’) Purpose
P1 CACCATGGTGAGCAAGGGCG egfp forward
P1c TTACTTGTACAGCTCGTCCATGC egfp reverse 
P2 CACCATGCGTGACGAGATGTGG ACE1 5’
P2c AAGCTTGCTCTCGGCAATATAC F1 reverse primer
P3 CACCATGCGTGACGAGATGTGGA ACE1 5’
P3c GCATTGAGCGAGTGGACTGGGCATTGTAATGCCTTTAGTCCGACCATCCT intron1 spanning
P4 GCATTACAATGCCCAGTCCA F5 forward
P4c GCTTGACCGCCTCGAGCGTG F5 reverse
P5 CCATGGTGAGATTCAGACAG intron2 forward
P5c TATCTCGTCGAGGTAGATGC intron2 reverse
P6 CGGTGACTGGTCTCCGTCTG intron3 forward
P6c TGCACAAATTCAAGCAGCAG intron3 reverse
P7 CACCTCCACGCCTCAACTCAACCG F11/F12 forward
P8 GTCGCTCAACGACTCGAGGAAGCTCATACGGATGGTGAGCAAGGGCGAGG egfp overlap forward
P9 TAGGTCAGGGTGGTCACGAG sequencing
P10 TGCGACTCACCCTGCTCAGC T10 forward
P10c AGAATGTCGAGCACTTCCTC T10 reverse
P11 TGACGACAAGCCGGATATCACGTGG T12 forward
P12 TTCTTCCGCGGCCGCCATGTACGGTCAAGATATTTTCCAA intron2 forward
P12c TTCTTCCACCATGGTGCTGCACGGTCGGTCACGTCG intron2 reverse
P13 TTCTTCCGCGGCCGCCATGATCAGGATGGTCGGACTAAAG intron1 forward
P13c TTCTTCCACCATGGAGTGGACTGGGCATTGTAATGC intron1 reverse
P14 TTCTTCCGCGGCCGCCATGAAGTGCTCGACATTCTCAAAG intron3 forward
P14c TTCTTCCACCATGGACCAGCTTTGCCGTGAATGCGT intron3 reverese
P15 TTCTTCATGCATAATTCTCTTATAACCGATGATCTG PACE1 forward
P15c TTCTTAGCGGCCGCGGTTGGTGATTTATTTGTTTGG PACE1 reverse
P16c TGTACAAGAAAGCTGGGTCGGCGCGCCTTAGGTCCCGTCCTTCAGCAGTC T12 reverse
P17c TGCACAAATTCAAGCAGCAG Recomb. site seq. primer
P18 GGCCTTTCCCAGACTGCTGAAGGACGGGACTAAAAGGGTGGGCGCGCCGACC forward adaptor to remove egfp
P19c TTACGCCCCGCCCTGCCACTC reverse primer to remove egfp
P20 TCTTTCAACACAAGATCCCAAAGTCAAAGGATGGCGCCGTTCATTCCCTCG forward to amplify RAP1
P21c GGTTGGCTGGTAGACGTCATATAATCATACCTACAGCCGCACAACAATCTTTT reverse to amplify RAP1
Table S1: Oligonucleotides used in this study
pENTR-D-TOPOegfp. The egfp gene was amplified by PCR using primers P1 and P1c and 
pPACE1ACE1egfphyg (obtained from Dr Jerome Collemare) as the template. The product was cloned 
into pENTR-D-TOPO (Invitrogen) using standard procedures.
pPamyBACE1egfpargB. The plasmid pPACE1ACE1egfphyg (obtained from Dr Jerome Collemare) 
was digested with HindIII and FseI and gel purified to give the fragment F1. pPACE1ACE1egfphyg 
was used as the template in a PCR reaction using primers P2 and P2c to form a 651 bp fragment (F2) 
consisting of the 5’ end of ACE1. F2 was cloned into pENTR-D-TOPO and the resulting plasmid was 
then digested with FseI and HindIII to form fragment F3. Fragment F1 was ligated into F3 to give 
pENTRACE1eGFP which was amplified in E. coli. In vitro Gateway LR recombination was used to 
mobilise ACE1 into pTAex3GS to form pPamyBACE1egfpargB.
pEYA1ACE1[intron1]. The plasmid pPACE1ACE1egfphyg (obtained from Dr Jerome Collemare) 
was used as a PCR template to generate a fragment in which intron-1 had been removed. A PCR 
fragment was amplified using primers P3 and P3c. The first part of P3c is the sequence after intron 1 
that will be used as a tailed overlap region with the next fragment while the second part of the sequence 
is a primer binding sequence just before intron 1. The PCR product from P3 and P3c was then cloned 
into pENTR-D-TOPO which was then used as a PCR template for amplifying fragment F4 using 
primers M13F and P3c. Fragment F5 was produced from a PCR using P4 and P4c. The PCR product 
was cloned using Zero-blunt PCR cloning Kit and the fragment F5 was released by EcoRI restriction 
digestion. The F5 fragment thus contains the region starting from just after intron 1 and ended at 50 bp 
after the SmaI restriction site that will form overlap with fragment F7. Fragment F7 was obtained by a 
SmaI/HindIII digest of pPACE1ACE1egfphyg followed by gel purification. pENTR-D-TOPOegfp was 
used as a template for PCR using primers P1 and M13R to give fragment F8, which contains, at its 3’ 
end, a region of sequence of pENTR-D-TOPO. Finally, yeast vector pEYA1 was digested with NotI 
and AscI and then recombined in yeast with fragments F4, F5, F7 and F8 to create 
pEYA1ACE1[intron1].
pPamyBACE1[introns1-3]egfpargB. Fragments F9 (470 bp) and F10 (469 bp) lacking introns 2 and 
3 respectively were obtained by PCR from two cDNA clones of ACE1 respectively in the region of 
intron 2 (5395-7434) and intron 3 (6805-9732) obtained from Dr Jerome Collemare using primer pairs 
P5/P5c and P6/P6c respectively. Fragment F11 was obtained by PCR from 
pEYA1ACE1[intron1]egfp using primers P7 and P1c. The yeast vector pEYA1ACE1[intron1] was 
digested with KpnI and AscI and gel purified and then recombined in yeast with F9, F10 and F11 to 
create pEYA1ACE1[introns1-3]egfp. This in turn was LR recombined with pTAex3·GS1 to create 
pPamyBACE1[introns1-3]egfpargB.
pPamyBACE1[introns1-3]argB. The plasmid pEYA1ACE1[introns1-3]egfp was used as a 
template in a PCR reaction using primers P18 and P19c to give T24. The plasmid 
pEYA1ACE1[introns1-3]egfp was linearised with Asc1 and then recombined with T24 in yeast to 
give the plasmid pEYAACE1[introns1-3]stop. Gateway in vitro recombination was then used to 
move ACE1 from pEYAACE1[introns1-3]stop into the destination vector pTAYA-GSpAGE/T21 to 
form pPamyBACE1[introns1-3]argB.
pPamyBACE1[introns 1-3]argBPadhRAP1. The RAP1 gene was amplified from pPniaDRAP1bar 
using primers P20 and P21c to give T25. The vector pTAYA-GSpAGE/T21 was linearised with Asc1 
and recombined with T25 in yeast to form the destination vector pTAYA-GS-RAP1. Gateway in vitro 
recombination was then used to move ACE1[introns1-3]stop from pEYAACE1[introns1-3]stop into 
pTAYA-GS-RAP1 to form pPamyBACE1[introns 1-3]argBPadhRAP1.
pAmyBACE1pks[introns1-2]egfpargB. The egfp gene was amplified using primers P8 and M13R 
using pEYAACE1[intron1]egfp as a template and then gel purified to give T8. 
pEYA1ACE1[intron1]was digested with MluI and the largest piece T2 was gel purified. T1, T2, and 
T8 concentrations were adjusted to be equaimolar following gel electrophoresis analysis. The latter 
three DNA pieces were transformed in yeast for recombination. The recombined plasmid extracted 
from yeast was cloned in E. coli for amplification and then extracted from five clones. Recombined 
plasmids extracted were tested for correctness via restriction analysis using AscI, NdeI, and SmaI. 
Correctly recombined plasmid pEYA1ACE1E1E2I2E3I3E4(518)·egfp was sent for sequencing the 
fusion site between egfp and the ACE1-part using primer P9. Intron-2 containing sequence was 
removed from pEYA1ACE1E1E2I2E3I3E4(518)·egfp using digestion with BaeI and the cut construct 
was gel purified to give T9. Intron-2 free ACE1 PCR product (corresponding to and larger than the 
removed one and hence recombinable with T9) was amplified using primers P10 and P10c and gel 
purified to give T10. Overlapping cDNA provided by Dr. Jerome Collemare, which were amplified by 
RT-PCR across intron-2 and intron-3 area using RNA extracted during appressorial expression of 
ACE1, were used as the template in the latter PCR. T9 and T10 were then recombined in yeast. The 
recombined plasmid extracted from yeast was cloned in E. coli for amplification and then extracted 
from five clones. Recombined plasmids extracted were tested for correctness via restriction analysis 
using AscI, NdeI, and SmaI. Correctly recombined plasmid pEYA1ACE1E1E2E3I3E4(518)egfp was 
sequenced using P10 and P10c primers to confirm intron-2 removal. 
pEYA1ACE1E1E2E3I3E4(518)egfp was LR recombined with pTAex3·GS1 leading to 
pAmyBACE1pks[introns1-2]egfpargB.
pPamyBACE1[introns1-2]argB. The vector pEYA1ACE1E1E2E3I3E4(518)egfp was digested with 
AscI and gel purified to give T11. The NRPS encoding sequence of ACE1 was amplified using P11 
and P16c primers and pPACE1ACE1egfphyg as the template to give T12 which was then gel purified. 
T11 and T12 were then recombined in yeast. The recombined plasmid extracted from yeast was cloned 
in E. coli for amplification and then extracted from five clones. Recombined plasmids extracted were 
tested for correctness via restriction analysis using AscI, NdeI, and SmaI. The site of recombination 
between T11 and T12 on the ACE1 sequence was checked by sequencing using primer P17c. The 
confirmed plasmid pEYA1ACE1E1E2E3I3E4 was LR recombined with pTAex3·GS1 leading to 
pPamyBACE1[introns1-2]argB.
pUC18hygPgpdAGS. The hph cassette (hygromycin resistance gene driven by the PtrpC promoter) 
was cloned into pUC18 at its KpnI site to create pUC18hyg. The PgpdA promoter was amplified by 
PCR using primers modified with HindIII and BamHI restriction sites at their 5’ termini. The PCR 
product was cloned into pCR4Blunt-TOPO (Invitrogen) which was then digested with HindIII and 
BamHI to give a 2164 bp fragment R1. The vector pUC18hyg was digested with HindIII and BamHI 
and gel purified to give a 4076 bp product R2. R1 was ligated into R2 to give pUC18hygPgpdA. The 
plasmid pUC18hygPgpdA was then digested with HindIII and gel purified to create R3. A Gateway 
cassette (i.e. attR1CmRccdbattR2) was amplified by PCR using primers each with HindIII restriction 
sites at their 5’ termini – this fragment was gel purified, digested with HindIII and then ligated into R3 
to create two vectors: pUC18hygPgpdAGS in which the Gateway cassette is cloned in the sense 
direction; and pUC18hygBPgpdAGS(anti) in which the Gateway cassette is cloned in the antisense 
direction.
pPgpdAACE1pks[introns1-2]egfphyg. pEYA1ACE1E1E2E3I3E4(518)·egfp was LR recombined 
with pUC18hygBPgpdAGS to give pPgpdAACE1pks[introns1-2]egfphyg.
pPgpdaACE1egfphyg. pENTRACE1eGFP was LR recombined with pUC18hygBPgpdAGS to form 
pPgpdaACE1egfphyg.
pPniaDRAP1bar. This was obtained from Dr Jerome Collemare.2
pPamyB·intron1egfp·argB. pENTR-D-TOPOegfp was digested with NotI and NcoI and gel purified 
to give T15. ACE1 intron-1 with 21 bp of exon-1 at its 5’-end and with 24 bp of exon-2 following its 
3’-end was amplified using P13 and P13c primers and pPACE1ACE1egfphyg was used as a template. 
P13 has a NotI site and P13c has an NcoI site, therefore, the amplified latter fragment was digested 
with both enzymes and then gel purified to give T16. T16 was cloned into T15 via ligation and then 
transformed into E. coli which was selected on LB plates with kanamycin. The recombined plasmid 
pENTRE1[21]I1E2[24]·egfp was confirmed by sequencing using M13F primer. 
pENTRE1[21]I1E2[24]·egfp was LR recombined with pTAex3·GS1 leading to 
pPamyB·intron1egfp·argB.
pPamyB·intron2egfp·argB. ACE1 intron-2 with 21 bp of exon-2 at its 5’-end and with 24 bp of exon-
3 following its 3’-end was amplified using P12 and P12c primers and pPACE1ACE1egfphyg as a 
template. P12 has a NotI site and P12c has an NcoI site, therefore, the amplified latter fragment was 
digested with both enzymes and then gel purified to give T17. T17 was cloned into T15 via ligation 
and then transformed into E. coli which was selected on LB plates with kanamycin. The recombined 
plasmid pENTRE2[21]I2E3[24]·egfp was confirmed by sequencing using M13F primer. 
pENTRE2[21]I2E3[24]·egfp was LR recombined with pTAex3·GS1 leading to 
pPamyB·intron2egfp·argB.
pPamyB·intron3egfp·argB. ACE1 intron-3 with 21 bp of exon-3 at its 5’-end and with 24 bp of exon-
4 following its 3’-end was amplified using P14 and P14c primers and pPACE1ACE1egfphyg as a 
template. P14 has a NotI site and P14c has an NcoI site, therefore, the amplified latter fragment was 
digested with both enzymes and then gel purified to give T18. T18 was cloned into T15 via ligation 
and then transformed into E. coli which was selected on LB plates with kanamycin. The recombined 
plasmid pENTRE3[21]I3E4[24]·egfp was confirmed by sequencing using M13F primer. 
pENTRE3[21]I3E4[24]·egfp was LR recombined with pTAex3·GS1 leading to 
pPamyB·intron3egfp·argB.
pPgpdA·intron1egfp·hyg. This construct was established by LR recombination of 
pENTRE1[21]I1E2[24]·egfp with pUC18hygBPgpdA·GS.
pPgpdA·intron2egfp·hyg. This construct was established by LR recombination of 
pENTRE2[21]I2E3[24]·egfp with pUC18hygBPgpdA·GS.
pPgpdA·intron3egfp·hyg. This construct was established by LR recombination of 
pENTRE3[21]I3E4[24]·egfp with pUC18hygBPgpdA·GS.
pPACE1·intron1egfp·hyg. The ACE1 promoter was amplified using P15 and P15c with 
pPACE1egfphyg used as a template. P15 has an NsiI site and P15c has a NotI site, therefore, the 
amplified latter fragment was digested with both enzymes and then gel purified to give T19. 
pPgpdA·intron1egfp·hyg was then digested with NsiI and NotI and gel purified to give T20. T19 was 
then cloned by ligation into T20 leading to pPACE1·intron1egfp·hyg.
pPACE1·intron2egfp·hyg. pPgpdA·intron2egfp·hyg was digested with NsiI and NotI and gel purified 
to give T21. T19 was then cloned by ligation with T21 leading to pPACE1·intron2egfp·hyg.
pPACE1·intron3egfp·hyg. pPgpdA·intron3egfp·hyg was digested with NsiI and NotI and gel purified 
to give T22. T19 was then cloned by ligation with T22 leading to pPACE1·intron3egfp·hyg.
pPgpdA·egfp·hyg. This construct was established by LR recombination of pENTR-D-TOPO·egfp with 
pUC18hygBPgpdA·GS
pPACE1·egfp·hyg. pPgpdA·egfp·hyg was digested with NsiI and NotI to remove the PgpdA sequence 
and gel purified to give T23. T19 was then cloned by ligation with T23 leading to pPACE1·egfp·hyg.
2. Transformation of A. oryzae and M. oryzae
2.1 Media
DPY agar medium. 20 g dextrin, 10 g polypeptone, 5 g yeast extract, 5 g KH2PO4, 0.5 g MgSO4, and 
15 g agar were dissolved in 1 liter of distilled water and sterilized by autoclaving at 121 °C for 15 
minutes at 15 psi. The DPY agar plates were inoculated with 1 to 2 mL of A. oryzae spores suspension. 
Inoculated plates were incubated for 13 to 15 days at 28 °C until sporulation which was assessed by 
inspection under light microscope.
Complete medium (CM). The CM broth medium was prepared by dissolving 10 g glucose, 2 g 
peptone, 1 g yeast extract, 1 g casamino acids, 6 g NaNO3, 0.5 g KCl, 0.5 g MgSO4, and 1.5 g KH2PO4 
in 1 litre distilled water. The pH was adjusted to 6.5. This is followed by autoclaving at 121 °C for 15 
minutes at 15 psi. Filter sterilized trace elements solution (7.9 mg·L-1 ZnSO4.7H2O, 0.6 mg·L-1 CuSO4, 
0.1 mg·L-1 H3BO3, 0.2 mg·L-1 MnSO4.H2O, and 0.14 mg·L-1 NaMoO4) was added in a final 
concentration of 0.1 % (v/v) to the latter medium after cooling down. Additionally, filter sterilized 
vitamin supplement (1 mg·L-1 thiamine, 5 mg·L-1 biotin) was added in a final concentration of 0.1 % 
(v/v). CM broth was prepared in 100 mL aliquots dispensed in 500 mL Erlenmeyer conical flasks. 
The autoclaved flasks containing the CM broth were inoculated with M. oryzae spores 
suspension for preparing to transformation. However, CM broth used for fermentation with purpose of 
compound production was modified by increasing sugar concentrations to 20 g·L-1 of glucose and 10 
g·L-1 of sucrose. The inoculated flasks were incubated at 25 °C for 2 - 7 days according to the 
experiment design.
CM agar medium was made by inclusion of 15 g·L-1 of agar to the CM broth medium prior to 
autoclaving and processed in the same way as previously mentioned. The M. oryzae inoculated plates 
were incubated at 25 ˚C for 10-12 days until growth and sporulation were obvious under microscope. 
Mycelia and spores were then collected by adding 2-3 mL of sterile water and scrapping the plates to 
inoculate different media. Storage was made by mixing the latter spore suspension as 1:1 to sterilized 
40 % glucerol and stored at - 80 °C.
STC buffer, 200 g·L-1 sucrose, 50 mM Tris-HCl, 50 mM CaCl2.2H2O, pH 7.5.
PTC buffer, 60 % PEG 3350, 1 M sorbitol, 50 mM Tris-HCl, 50 mM CaCl2.2H2O, pH 7.5.
TB3 recovery medium, 200 g·L-1 sucrose, 3 g·L-1 yeast extract.
TNK-CP agar medium. The TNK-CP agar medium was made by dissolving 10 g glucose, 2 g yeast 
extract, 15 g agar, 2 g NaNO3, 2 g KH2PO4, 0.5 g MgSO4.7H2O, 0.1 g CaCl2.2H2O, and 4 mg 
FeSO4.7H2O in 1 litre of distilled water. The pH of the medium is adjusted to 5.5 - 5.8. This is followed 
by autoclaving at 121 °C for 15 minutes at 15 psi. Filter sterilized trace elements solution and filter 
sterilized vitamin supplement (see CM medium) were added in concentration of 0.1 % (v/v) each to the 
latter medium after cooling down. They were added before dispensing the medium into plates. 
TNK-CP-Su-Hyg medium. TNK-CP-Su-Hyg has the same components of and prepared in the same 
way as TNK-CP medium with the addition of 200 g·L-1 sucrose before autoclaving and addition of 
hygromycin B in a final concentration of 240 mg·L-1 before use.
TNK-CP-Hyg medium. TNK-CP-Hyg has the same components and is prepared in the same way as 
TNK-CP medium with the addition of hygromycin B in a final concentration of 120 mg·L-1 before use.
Glucose medium. 20 g glucose, 10 g peptone and 30 g sucrose containing CD for A. oryzae 
transformants.
Starch medium. 20 g starch and 10 g peptone containing CD for A. oryzae transformants and CM for 
M. oryzae transformants.
2.2 Transformation of A. oryzae. 
A 150 μL spore suspension of A. oryzae strain M-2-3 was spread onto DPY agar plates incubated at 30 
°C for 7 - 10 days. Sterile water (5 mL) was added and the spores scraped off with a sterile loop. The 
liquid was collected and inoculated into DPY growth medium (100 mL) which was then incubated at 
30 °C with shaking (200 rpm, 24 h). Mycelia were collected by filtration through sterile filter paper, 
washed with sterile water, then washed with 0.9 M sodium chloride, and centrifuged (10 000 g, 10 min) 
and the supernatant was discarded. Filter-sterilized protoplasting solution (Trichoderma harzianum 
lysing enzymes, 20 mg·mL-1; Driselase enzyme, 10 mg·mL-1; NaCl, 0.9 M, 20 mL) was added to the 
biomass which was resuspended thoroughly by vortexing.
The tube was incubated at 25 oC, with gentle mixing on a rotator. Sufficient protoplast formation 
was checked by microscope every 30 min. The protoplasts were filtered through sterile Miracloth. The 
filtrate was gently centrifuged (700 g, 5 min) and the supernatant was removed. The obtained 
protoplasts were washed with 0.9 M NaCl and with Solution I gently and centrifuged (700 g, 5 min). 
The concentration of protoplasts was determined by using a haemocytometer (Fisher). The protoplasts 
were resuspended in Solution I (0.9 M NaCl, 50 mm CaCl2, 50 mm Tris-HCl, pH 7.5) to give 2.5 × 108 
protoplasts·mL-1 and stored on ice. Then Solution II (60% PEG 3350, 0.9 M NaCl, 50 mM CaCl2, 50 
mM Tris-HCl, pH 7.5) (about 1/5 volume of the protoplast solution) was added and mixed gently. 
Then 0.2 mL of the obtained mixture was added into 10 mL sterile tubes. DNA (5-10 μg, 20 μL 
maximum) to be transformed into the fungus was added to the 0.2 mL protoplast suspension and 
incubated on ice (30 min). Solution II (1 mL) was added and mixed gently, then incubated at room 
temperature (20 min). Czapek-Dox agar (Oxoid) in sorbitol (1 M; 8 mL; lower than 45 °C) was added 
to the transformation mixture and overlaid onto Czapek-Dox agar with sorbitol (1 M; 15 mL) plates. 
The plates were incubated at 30 °C for 4 - 6 days. The transformants were picked using a sterile 
toothpick and transferred to Czapek-Dox agar plates. Two rounds of selection on Czapek-Dox media 
were further performed. The genuine argB transformants were then grown on DPY agar for 7 - 10 days 
for spore production. These transformants were then stored at 4 °C and selected for chemical analysis.
2.3 Transformation of M. oryzae.
M. oryzae strain used in this research was the Guy11 strain known to be sensitive to both hygromycin 
B as well as Basta antibiotics. Constructs used for transformation and expression in M. oryzae Guy11 
contained the hygB or bar cassettes.
M. oryzae was grown on CM plates for 10 - 12 days. A plug of the medium with fungal mycelia 
was aseptically transferred to 50 - 100 mL sterilized CM broth in a 500 mL Erlenmeyer conical flask. 
The flask was incubated at 25 ˚C for 3 - 4 days with shaking at 150 rpm. Mycelia were homogenised 
(IKA T18 basic homogonizer) and transferred to a new CM broth medium followed by incubation 
under the same conditions for 1 - 2 days. Mycelia were collected by filtration, and protoplasting was 
performed using Trichoderma harzianum lysing enzymes (20 mg·mL-1) and Driselase enzyme (10 
mg·mL-1) in NaCl (0.9 M) with gentle shaking at room temperature for 2 - 3 h. Protoplasts were filtered 
through miracloth and centrifuged at 2000 rpm for 10 min. Protoplasts were then resuspended (washed) 
in sterilized STC buffer  and centrifuged again at 2000 rpm for 10 minutes. 
Protoplasts were diluted to 3 x 107·mL-1 in STC buffer and approximately 5 μg (20 μl) of 
appropriate plasmid was added to 200 mL protoplast solution. The mixture was incubated on ice for 30 
min, 1 mL of filter sterilized PTC buffer was then added and the mixture was incubated at room 
temperature for a further 30 min. 4 – 5 mL of sterilized TB3 recovery medium was added to the 
concentrate and left to be shaken very gently overnight. The mixture was centrifuged at 3000 rpm and 
supernatant was reduced to 1 mL for concentration. The concentrate was then mixed with 19 mL of 
molten TNK-SU-CP-Hyg containing 240 μg·mL-1 hygromycin B at 45 - 50 C and mixed well then 
poured in plates. Plates were incubated at 25 - 28 C for 5-7 days with daily observation until most or all 
colonies of transformants appeared. Transformants were then further selected on TNK-CP-Hyg plates 
(2ndry transformation plates) containing 120 μg·mL-1 hygromycin B. Finally, clones grown on 2ndry 
plates were purified to single spores and used or stored.
Co-transformation of M. oryzae Guy11 with both hygB containing ACE1 construct with pNIA-
RAP1 containing bar gene was achieved in two stages. An ACE1 expressing M. oryzae transformant 
was transformed with the pNIA-RAP1 following the method mentioned above. Basta in a concentration 
35 μg·mL-1 was used in addition to hygromycin B for the selection of these co-transformants.
2.4 Fermentation of A. oryzae transformants and extraction
Sterile water (5 mL) was added to the transformant plate and the spores scraped off with a sterile loop. 
The suspensions (200 μL) obtained from transformants were inoculated into glucose medium (100 mL) 
to repress expression. The flasks were incubated at 30 °C with shaking at 200 rpm for 3 days. The 
medium was then replaced with fresh liquid minimal media containing starch for induction and 
incubated at 30 °C with shaking at 200 rpm for 3 days.
The culture broth was acidified using 2 M hydrochloric acid until the solution reached pH 4.0. 
The mycelia were homogenised using a hand-held kitchen blender and separated by filtration. The 
obtained broth was extracted three times with 1 volume of ethyl acetate. The mycelia were stirred in 
acetone for 12 h, filtered to remove solids. The acetone was removed by evaporation at reduced 
pressure and the remaining aqueous  layer was extracted with ethyl acetate. The ethyl acetate extract, 
after being dried over anhydrous MgSO4, was evaporated at reduced pressure. The residue was 
dissolved in 2 mL methanol, diluted and used for LC-MS analysis.
2.5 Modified extraction of A. oryzae transformants
After fermentation, the resultant culture was homogenised using a hand-held kitchen blender and 
vacuum- filtered through filter paper. The liquid medium was extracted by equal amount of ethyl 
acetate once. The medium was acidified to pH 4-5 by 2M HCl and extracted again with an equal 
volume of ethyl acetate. The two parts of ethyl acetate extract were combined, dried over anhydrous 
MgSO4 and the liquid was evaporated at reduced pressure. The residue was dissolved in MeOH for 
LCMS analysis (referred to as “medium” samples). Additionally, the cell filtrate was placed in acetone 
for 2 hours whilst stirring. The acetone was evaporated at reduced pressure and the remaining liquid 
was extracted once with 50 mL of ethyl acetate.  The resultant organic layer was dried over anhydrous 
MgSO4 and the liquid was evaporated at reduced pressure. Afterwards, the dried compounds were 
dissolved in 2 mL methanol, diluted and used for LC-MS analysis (referred to as “cells” samples).
2.6 Fermentation of M. oryzae transformants and extraction
M. oryzae transformants with ACE1 constructs were inoculated in a sterilized modified CM broth (100 
mL  7 Erlenmeyer flasks with 500 mL capacity) for 6 - 7 days at 25 °C and 150 rpm shaking condition. 
M. oryzae co-transformants with ACE1 and RAP1 were inoculated under the same condition. Basta 
antibiotic was added to the test flasks to keep selection of transformants, while flasks inoculated with 
contol fungi were not supplemented with Basta. The cultures were then segregated into mycelia 
fraction and aqueous phase which were treated, extracted, evaporated and analysed the same way as A. 
oryzae. The pyrone from M. oryzae was extracted from both the aqueous phase and the separated 
mycelia.
3. LCMS Procedures
Samples were dissolved in MeOH to 1 mg·mL-1, centrifuged for 5 min at 13, 500 rpm, and the 
supernatant was analysed by LCMS using a Waters 2795HT HPLC system. Detection was achieved by 
uv between 200 and 400 nm using a Waters 2998 diode array detector, and by simultaneous 
electrospray (ES) mass spectrometry using a Waters ZQ spectrometer detecting between 150 and 600 
m/z units. Chromatography (flow rate 1 mL·min-1) was achieved using either Phenomenex LUNA 
column (5 μ, C18, 100 Å, 4.6 × 250 mm) equipped with a Phenomenex Security Guard precolumn 
(Luna C5 300 Å) or a Phenomenex Kinetex column (2.6 μ, C18, 100 Å, 4.6 × 100 mm) equipped with a 
Phenomenex Security Guard precolumn (Luna C5 300 Å). Solvents were: A, HPLC grade H2O 
containing 0.05% formic acid; B, HPLC grade MeOH containing 0.045% formic acid; and C, HPLC 
grade CH3CN containing 0.045% formic acid). Gradients were as follows.
Method 1. Luna/MeOH: 0 min, 25% B; 5 min, 25% B; 51 min, 95% B; 53min, 95% B; 55 min, 25% B; 
59 min, 25% B; 60 min, 25% B.
Method 2. Luna/CH3CN: 0 min, 5% C; 5 min, 5% C; 45 min, 75% C; 46 min, 95% C; 50 min, 95% C; 
55 min, 5% C; 60 min, 5% C.
Method 3. Kinetex/MeOH: 0 min, 10% B; 10 min, 90% B; 12 min, 90% B; 13min, 10% B; 15 min, 
10% B.
Method 4. Kinetex/CH3CN: 0 min, 10% C; 10 min, 90% C; 12 min, 90% C; 13min, 10% C; 15 min, 
10% C.
Semi-Preparative LCMS and compound purification.
Purification of compounds was generally achieved using a Waters mass-directed autopurification 
system comprising of a Waters 2767 autosampler, Waters 2545 pump system, a Phenomenex LUNA 
column (5μ, C18, 100 Å, 10 × 250 mm) equipped with a Phenomenex Security Guard precolumn (Luna 
C5 300 Å) eluted at 4 mL/min at ambient temperature. Solvent A, HPLC grade H2O + 0.05% formic 
acid; Solvent B, HPLC grade CH3CN + 0.045% formic acid. The post-column flow was split (100:1) 
and the minority flow was made up with MeOH + 0.045% formic acid to 1 mL·min-1 for simultaneous 
analysis by diode array (Waters 2998), evaporative light scattering (Waters 2424) and ESI mass 
spectrometry in positive and negative modes (Waters Quatro Micro). Detected peaks were collected 
into glass test tubes. Combined tubes were evaporated under a flow of dry N2 gas, weighed, and 
residues dissolved directly in NMR solvent for NMR analysis.
30 minute ramp program: 5% B to 60% B for magnaporthepyrones purification, 45% B to 95% B for 
compound 8 purification over 25 min, 95%B to 5%B over 2 min, hold for 5 min. 
4. Characterisation of new natural products.
12,13-Dihydroxymagnaporthepyrone 6. Isolated as an amorphous yellow solid (15 mg) and a 
1:1 mixture of two diasteroisomers (A and B) by preparative HPLC. 1H NMR (500 MHz 
Acetone-d6):  1.09 ppm (1.5H, d, 3JHH 6.7, H-14A), 1.11 ppm (1.5H, d, 3JHH 6.3, H-14B), 
1.255 (1.5H, s, H-15A), 1.260 (1.5H, s, H-15B), 2.02 (1.5H, s, H-16A), 2.03 (1.5H, s, H-16B), 
3.60 (0.5H, q, 3JHH 6.7, H-13A), 3.61 (0.5H, q, 3JHH 6.3, H-13B), 5.39 (1H, d, 3JHH 2.0, H-2A + 
H-2B), 6.07 (0.5H, d, 3JHH 15.3, H-11A), 6.08 (0.5H, d, 3JHH 15.3, H-11B),6.20 (1H, d, 3JHH 
2.0, H-4A + H-4B), 6.55 (1H, m, H-10AB), 6.69 (2H, m, H-8AB + H-9AB), 7.09 (1H, d, 3JHH 
9.6, H-7AB); 13C NMR (151 MHz Acetone-d6):  12.7 ppm (C-15), 18.1 & 18.3 (C-14), 24.5 
& 23.7 (C-16), 74.2 (C-13), 75.8 (C-12), 90.1 (C-2), 99.0 (C-4), 126.8 (C-6), 128.2 (C-8), 129.5 
& 129.8 (C-10), 132.5 (C-7), 139.6 & 139.6 (C-9), 142.8 & 143.2 (C-11), 162.4 (C-3/5), 162.6 
(C-5), 163.6 (C-1), 170.7 (C-3); UV/vis max (H2O/MeOH) 273, 362 nm; IR max (neat) 3375 
brs, 2926, 1685 br s, 1530 cm-1; MS (ESI+) m/z (%): 293 (100) [M]H+, 315 (50) [M]Na+; MS 
(ESI-) m/z (%): 291 (100) [M - H]-; HRMS (ESI-) calculated [M - H]- 291.1238; found 
291.1238.
Figure S1A. 1H NMR of 6.
Figure S1B. 1H NMR of 6.
Figure S1C. 1H NMR of 6.
Figure S1D. 1H NMR of 6.
Figure S1E. 1H NMR of 6.
Figure S1F. 1H COSY NMR of 6.
Figure S1G. HSQC NMR of 6.
Figure S1H. HMBC NMR of 6.
Acetate labelling
A culture of A. oryzae pTAex3ACE1eGFP was supplemented with sodium [1,2-13C2] acetate, 2 
and 3 days after inoculation to a final culture concentration of ~ 6 mM. After incubation for 5 
days 12,13-dihydroxymagnaporthepyrone 6 (10 mg) was purified and analysed by 13C NMR. 
The resulting spectrum was compared to a spectrum of unlabelled 12,13-
dihydroxymagnaporthepyrone 6 (Figure S1).
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Figure S1I: 13C NMR of 12,13-dihydroxymagnaporthepyrone 6. B: 13C NMR of 12,13-
dihydroxymagnaporthepyrone 6 from [1,2-13C2] acetate  labelling study with expansions (C-H)
Analysis of the 13C NMR spectrum of the 12,13-dihydroxymagnaporthepyrone 6 isolated in 
the  [1,2-13C2] acetate isotopic labelling study revealed evidence for intact isotopic enrichment 
at all positions in the carbon backbone with the exception of the two side chain methyl groups 
(C-15 and C-16). 
The resonance corresponding to C-3 was very weak which meant no satellites could be 
observed, however the coupled partner C-4 shows coupling to C-3 (coupling constant analysis 
rules out coupling to C-5 which shows a coupling to C-6). Signals corresponding to C-12 and 
C-13 were both weak and complicated by the mixture of diastereoisomers. Broad peaks appear 
coalesced with the satellites in both cases. The coupling constants for peaks corresponding to 
incorporation at C-12 and C-13 could not be extracted, but the effect of coupling was evident 
on each respective coupling partner (C-11 & C-14). The labelling pattern observed in 12,13-
dihydroxymagnaporthepyrone 6 following supplementation with [1,2-13C2] acetate, shows that 
the carbon skeleton of 12,13-dihydroxymagnaporthepyrone 6 is entirely derived from acetate.
Methionine labelling of 6.
A seed culture of A. oryzae pTAex3ACE1eGFP in three 500 ml flasks (containing 100 ml medium in 
each flask) was incubated for 3 days (72 h) in medium containing glucose (CD + 1% polypeptone + 2% 
glucose). The medium was removed and replaced with production medium containing starch (CD + 1% 
polypeptone + 2% starch). 45 mg [methyl-13C]-methionine was dissolved in 3 ml sterile water and 
filtered through 0.2 m syringe filter device for sterilisation. 0.5 ml of the solution was added to each 
flask respectively at the 48 h and 72 h fermentation (final concentration of [methyl-13C] methionine to 
each flask was 1 mM). The culture was harvested after 96 h fermentation. The culture filtrate was 
extracted with ethyl acetate twice. The target compound was then purified by LCMS (< 0.5 mg).
Figure S2A. 13C NMR spectrum of 6 labelled with [methyl-13C]-methionine. Note that NMR 
solvent is CD3OD.
10,11-Dihydroxymagnaporthepyrone 7. Isolated 8 mg by preparative HPLC. 1H NMR (500 
MHz Acetone-d6):  1.60 (3H, d, 3JHH 7.2, H-14), 1.65 (3H, s, H-16), 2.00 (3H, s, H-15), 3.93 
(1H, d, 3JHH 7.2, H-11), 4.25 (1H, dd, 3JHH 7.7, 3JHH 7.7, H-10), 5.36 (1H, d, 4JHH 2.0, , H-2), 
5.50 (1H, q, 3JHH 7.7, H-13), 6.16 (1H, d, 4JHH 2.0, H-4), 6.30 (1H, dd, 3JHH 15.7, 3JHH 15.7, H-
9), 6.76 (1H, dd, 3JHH 15.2, 3JHH 15.4, H-8), 7.02 (1H, d, 3JHH 15, H-7); 13C NMR (151 MHz 
Acetone-d6):  12.1 ppm (C-14), 12.8 (C-16), 13.2 (C-15), 73.7 (C-10), 81.0 (C-11), 90.8 (C-
2), 99.0 (C-4), 122.1 (C-13), 126.3 (C-6), 126.3 (C-8), 132.2 (C-7), 136.8 (C-12), 142.0 (C-9), 
162.0 (C-5), 163.6 (C-1), 170.8 (C-3); UV/vis max (H2O/MeOH) 248, 340 nm; MS (ESI+) m/z 
(%): 293 (100) [M]H+, 315 (50) [M]Na+; MS (ESI-) m/z (%): 291 (100) [M - H]-; HRMS (ESI-) 
calculated [M - H]- 291.1238; found 291.1238. HRMS (ESI+) calculated [M]Na+ 315.1203; 
found 315.1204.
Figure S3A. 1H NMR spectrum of 7
Figure S3B. 13C NMR spectrum of 7.
Figure S3C. COSY NMR Spectrum of 7.
Figure S3D. HSQC NMR spectrum of 7.
Amide 8. 1H NMR (500 MHz, CDCl3):  0.92 ppm (d, 3H, J = 6.8), 1.35 (m, 2H), 1.51 (m, 
2H), 1.56 (s, 3H), 1.72 (d, 3H, J = 9.1), 1.74 (s, 3H), 1.95, (t, 2H, J = 7.5), 2.03 (t, 2H, J = 7.1), 
2.41 (m, 1H), 2.47 (m, 2H), 2.76 (dd, 1H, J = 7.4, 13.9), 2.81 (dd, 1H, J = 7.1, 13.9), 3.31 (d, 
1H, J = 17.2), 3.34 (d, 1H, J = 17.2), 3.57 (m, 1H), 3.68 (m, 1H), 4.15 (m, 1H), 4.91 (d, 1H, J = 
9.3), 5.52 (q, 1H, J = 6.8), 5.61 (ddd, 1H, J = 14.6, 7.3, 7.3), 6.05 (dd, 1H, J = 14.3, 9.3), 6.08 
(dd, 1H, J = 14.6, 9.3), 6.13 (d, 1H, J = 14.6), 6.75 (brd, 2H, J = 8) ,7.06 (brd, 2H, J = 8), 7.2 
(brd, 1H, J = 7.8); 13C NMR (125 MHz, CDCl3): 14.6 ppm, 16.6, 18.8, 23.4, 25.4, 29.8, 
35.4, 38.8, 41.9, 43.6, 46.4, 51.2, 56.1, 67, 118.1, 128.9, 129.2, 132.0, 133, 133.7, 134.6, 134.8, 
135.8, 137.4, 138.1, 157.2, 169, 209.7. HRMS ESI [M]H+: found 482.32649; predicted for 
C30H43NO4 482.32703.
Figure S4A. 1H NMR spectrum of 8.
Figure S4B. 13C NMR spectrum of 8.
Figure S4C. COSY spectrum of 8.
Figure S4D. HMBC spectrum of 8.
Figure S4E. HSQC spectrum of 8.
Summary Table 2D NMR Data for 8
Position C H m J/Hz HSQC HMBC H to COSY
A 14.6 1.74 s CH3 U, BB, CC -
B 16.6 1.72 d 9.1 CH3 BB, U U
C 18.8 1.56 s CH3 X, AA, K -
D 23.4 0.92 d 6.8 CH3 I, L, X I
E 25.4 1.51 m CH2 F, K, M, FF M, F
F 29.8 1.35 m CH2 E, K, M, AA E, K
I 35.4 2.41 m CH
D, L, X, AA, 
Z D, L, X
J 38.8 2.76, 2.81 dd, dd 7.4, 13.9 - 7.1, 13.9 CH2 P, Q, W P
K 41.9 1.95 t 7.5 CH2 C, E, F, X, AA F
L 43.6 2.03 t 7.1 CH2 D, I, Y, Z, X I, Z
M 46.4 2.47 m CH2 E, F, FF, E
N 51.2 3.31, 3.34 d, d 17.2, 17.2 EE, FF N geminal
P 56.1 4.15 m CH J J, Q, NH
Q 67 3.57, 3.68 m, m CH2 J, P Q geminal, P
S 118.1 6.75 brd 8 2 x CH S, V, DD W
T 128.9 6.08 dd 14.6, 9.3 CH CC, BB, Y, Z Y, CC
U 129.2 5.52 q 6.8 CH A, B, CC B
V 132 - - - Q - -
W 133 7.06 brd 8 2 x CH J, DD S
X 133.7 4.91 d 9.3 CH C, D, I, K, L, I
Y 134.6 6.05 dd 14.3, 9.3 CH T, CC, L T, Z
Z 134.8 5.61 ddd 14.6, 7.3, 7.3 CH I, L, T Y, L
AA 135.8 - - - Q - -
BB 137.4 - - - Q - -
CC 138.1 6.13 d 14.6 CH A, T, U, Y, Z T
DD 157.2 - - - Q - -
EE 169 - - - Q - -
FF 209.7 - - - Q - -
NH - 7.2 brd 7.8 NH EE P
5. Biological Testing of 6 - 8.
Rice plants of cultivars with (C101LAC, IR64) or without resistance gene Pi33 (CO39, Maratelli, 
Sariceltik), were grown in pots placed in a greenhouse for four weeks (4-5 leaf stage), as previously 
described3. The last fully developed rice leaf was attached to a horizontal board and wounded by 
pressing with a pipet tip at four locations. A 10 µL droplet of a metabolite or control solution was 
deposited on the wounded area. In some experiments, a drop of 15 µL corresponding to a spore 
suspension of a M. oryzae isolate virulent on Pi33 (PH19, see reference 3) was added to the wounded 
site, after evaporation of the metabolite droplet (1-3 hours). The cover of a Petri dish was placed on 
each leaf and plants were placed in a dew chamber overnight at 22 °C and saturating humidity. Plants 
were then moved back to the greenhouse and symptoms were observed from the first day after 
inoculation up to 7 days. Compounds were dissolved in Methanol (MeOH) at 10-1 M and diluted in 
water to 10-2 and 10-3 M, reaching final methanol concentrations of 100, 10 and 1%, respectively. Each 
metabolite and control solutions (MeOH, water) were deposited at 4 locations on 4 rice leaves (16 
points). The experiment was repeated twice independently.
6. Reverse-Transcription Analysis of ACE1 Introns
The RT-PCR products obtained for each of the three ACE1 introns were cloned into pGEM-T-Easy 
Vector and sequenced. The resulting sequences were aligned (Figure S5).  
A
35 13340 50 60 70 80 90 100 110 120(35)
CTAAAGGTACAAATGACCCCATTTGTTGGTGTTTGAGTTTTGACGTAAAAGATGGGGTTGGCTAATTTTCTTGATTGTGAACAAACACAAAAGGCATTAace1 (35)
CTAAAG---------------------------------------------------------------------------------------GCATTART-PCR A. oryzae (35)
CTAAAG---------------------------------------------------------------------------------------GCATTART-PCR M.grisea (35)
B
35 13740 50 60 70 80 90 100 110 120(35)
TTCCAAGTAAGTTTTGCTTTTGTTATTCGCGATGTCATGTCTAAACTCCAGTCTACTAAACCGTACAACCACTTTCGTTTTACCCTTGCCCCAATAGCGACGTace1 (35)
TTCCAA---------------------------------------------TCTACTAAACCGTACAACCACTTTCGTTTTACCCTTGCCCCAATAGCGACGTRT-PCR A. oryzae (35)
TTCCAA-------------------------------------------------------------------------------------------CGACGTRT-PCR M. grisea (35)
C
35 11640 50 60 70 80 90 100(35)
TCAAAGGTATTGTTGCTCATCTGCTCATCCTTTTTCTCCGAGCTGGTTTTTACTGACATGTTCCACGCAAATCCAGACGCATace1 (35)
TCAAAG----------------------------------------------------------------------ACGCATRT-PCR A. oryzae (35)
TCAAAG----------------------------------------------------------------------ACGCATRT-PCR M. grisea (35)
Figure S5. Alignment of sequencing results after RT-PCR. A, across intron-1 splicing area following expression in A. oryzae and M. oryzae; B, across intron-2 
splicing area following expression in A. oryzae and M. oryzae; C, across intron-3 area following expression in A. oryzae and M. oryzae.
7. Bioinformatic Analysis and Discussion of the ACE1 C-terminal domain.
The terminal R domain of PKS-NRPS enzymes are known to offload the polyketide-amino acid 
intermediate in two possible ways; via a Dieckmann cyclisation (DKC) to generate a tetramic acid 
moiety6 or via a reductive release.7 Walsh and co-workers studied the α-cyclopiazonic acid synthase 
(CpaS) R* domain from Aspergillus sp., by heterologous overproduction of the terminal domains in E. 
coli and determined that the R* domain catalyses a Dieckmann type cyclisation and does so without the 
participation of NAD(P)H, concluding that R* domains do not function as reductases.8 They further 
investigated the CpaS R* domain to identify residues that contribute to its redox-independent cyclase 
activities and observed that mutations in the Ser-Tyr-Lys catalytic triad, notably Tyr  to Phe / Leu, 
abolish the reductase activity.  
Characterization of the R domain of equisetin synthase (EqiS) appeared to contradict Walsh and 
co-workers’ results.  The EqiS R domain has a conserved Ser-Tyr-Lys catalytic triad which is expected 
for reductive domains, however over-expression of the R domain in E. coli determined that the R 
domain did not perform a reducing function nor did it bind reducing co-factors.9 Recently it has 
emerged that EqiS is not the PKS-NRPS responsible for equisetin biosynthesis, but is the PKS-NRPS 
responsible for fusaridione A biosynthesis and has been reassigned as fsdS.10 Therefore, the exact 
nature of the equisetin synthase (renamed eqxS) R domain is currently unknown. The initial 
experiments investigating eqiS (now fsdS) used synthetic precursors based on the structure of equisetin 
substrate mimics and not fusaridione substrate mimics, perhaps questioning the validity of the DKC 
activity assignment. Although fsdS has been over-expressed in its native host Fusarium heterosporum 
and did appear to function as a DKC to produce fusaridione A, the compound was unstable and 
degrades via a reverse-Dieckmann reaction to open the pyrrolidinedione ring. Since fsdS was expressed 
in its native host there is a possibility that another enzyme was active at the same time, facilitating the 
Dieckmann cyclisation. Therefore, the exact functions of the R domains from eqxS and fsdS remain 
ambiguous.
A multiple sequence alignment of several characterized PKS-NRPS R domains (Figure S6) 
appears to distinguish R* (DKC) domains from reducing (R) domains based on the Tyr to Phe / Leu 
mutation in the catalytic triad. Tenellin synthase (TENS), cyclopiazonic acid synthase (CpaS), 
desmethylbassianin synthase (DmbS) and aspyridone synthase (ApdA) are known to arise via a 
Dieckmann cyclisation and all have either a Phe or Leu mutation in the Ser-Tyr-Lys catalytic triad. 
ACE1, fusarin synthase (FusS), cytochalasin synthase (ccsA), chaetoglobosin synthase (CheS), 
pseurotin synthase (PsoA) and the uncharacterized synthase SYN2 are assigned as reductive domains 
based on the conserved Ser-Tyr-Lys motif. Experimental evidence from heterologous expression 
confirms that ACE1 and ccsA11 use a reductive release and experimental evidence from gene knock 
outs in the fusarin gene cluster also suggests a reductive release.7 The R domain activity of CheS and 
PsoA has not yet been confirmed to the best of our knowledge. The eqxS and fsdS R domains are also 
assigned as reducing domains based on the alignment and since the experimental evidence reported 
does not fully disprove this, and it is out of the scope of the project to investigate them further, the 
assignment appears valid for the time being. 
Figure S6. Sequence alignment of the C-terminal domain from fungal PKS-NRPS utilizing both the DKC mode of release (TENS, CpaS, CpaS2, DmbS and ApdA) and a 
predicted reductive release (ACE1, FusS, ccsA, CheS, eqxS, fsdSPsoA and SYN2). Sequences were obtained from NCBI and submitted to antiSMASH4 to identify 
domain boundaries. The resultant C-terminal domains were aligned using Geneious.5 The black box indicates the conserved NADH/NADPH binding domain; the 
solid squares indicate the SDR Ser-Tyr-Lys catalytic triad; the red square indicates the Tyr -> Phe / Leu mutation which abolishes the reductase activities. R 
represents the abbreviation of reductase. Protein name abbreviations: TENS (tenellin synthase), CpaS (cyclopiazonic acid synthase, A. flavus NRRL3357), CpaS 2 
(cyclopiazonic acid synthase, A. oryzae NBRC4177), DmbS (desmethylbassianin synthase), ApdA (aspyridone synthase), FusS (fusarin synthase), ccsA (cytochalasin 
synthase, ACLA_078660, CheS (chaetoglobosin synthase, CHGG_01239), eqxS (equisetin synthase), fsdS (fusaridione synthase), PsoA (pseurotin synthase), SYN2 
(uncharacterised synthase). 
8. Comparative analysis of the ACE1, CHGG1239 and ccs PKS-NRPS gene clusters
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BC2
08386
Zn(II)2Cys6 
transcription 
factor
01237 Zn(II)2Cys6 
transcription 
factor
22% ccsR
078640
Transcriptio
n activator
11%
OXR2
15927
FAD oxidase 01242-2 FAD oxidase 46% n/a n/a n/a
CYP2
15928
P450 
monooxygenase
01242-1 P450 
monooxygen
ase
37% ccsG
078710
P450 
monooxyge
nase
37%
MFS1
08384
MFS transporter n/a n/a n/a n/a n/a n/a
ORF3
08381
Unknown 01241 Unknown 46% ccsF
078690
Unknown 64%
Table S2 A comparison of the ACE1 gene cluster with the characterized gene clusters for 
chaetoglobosin (CHGG1239 gene cluster from Chaetomium globosum) and cytochalasin (ccs gene 
cluster from Aspergillus clavatus NRRL 1) biosynthesis.  * Percentage values represent protein identity 
to ACE1 cluster homologs.
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